Skip to main content
. 2020 Jul 14;12(7):1901. doi: 10.3390/cancers12071901

Figure 2.

Figure 2

Targeting telomeric components and telomerase as a potential therapeutic approach against human malignancies. TRF1 inhibitors such as ETP-47228, ETP-47037 block the TRF1 binding at the site of telomeres and prevent the formation of a shelterin complex to eradicate cancer cells. Several classes of telomerase inhibitors including nucleoside analogs, oligonucleotides, nonnucleoside, nutraceuticals, Isothiazolone derivatives, G4-DNA stabilizer.